Searched for
TOANSA PLANT
Ranbaxy gains over 2% as EU lifts export ban on Toansa unitThe European drug regulator has said that drugs from the Ranbaxy’s Toansa unit are fine. The regulator also said that the corrective measur...- EU lifts drug export ban from Ranbaxy's Toansa plantThe assessment of the Toansa facility by EMA followed an inspection by the USFDA, which revealed areas of non-compliance with GMP at the si...
- Exports to Europe from Ranbaxy's two plants to remain suspendedExports from Ranbaxy plants at Toansa and Dewas to Europe will remain suspended as probes are continuing, European health regulator EMA sai...
- Ranbaxy Laboratories' TL Easwar of API quits post ‘introspection’A few weeks after the meeting, its head of API manufacturing, TL Easwar, left the company, two people with direct knowledge of the matter t...
- Ranbaxy suspends shipments of active ingredients from Toansa, Dewas plantsRanbaxy Laboratories said Tuesday it was suspending shipments from two of its plants following US import bans on its products over safety c...
- Ranbaxy recovers from fall; suspends shipments from two plantsReacting to the news, shares of the drug maker plunged as much as 2.3 per cent in trade on the BSE, but recouped early morning losses quick...
- Ranbaxy slips as USFDA refuses request to allow exports from banned unitsThe USFDA prohibited Ranbaxy Labs from manufacturing and distributing APIs from its Toansa plant for FDA-regulated drug products.
- Do not support sabotage theory for Toansa plant: RanbaxyRejecting sabotage theory at Toansa plant that faces USFDA ban, Ranbaxy denied blaming company's voluntary retirement scheme for problems i...
- Brokerages cautious on Ranbaxy post Q4 show; stock down over 20% in 2014Analysts have maintained their cautious stance on Ranbaxy Laboratories even though the drugmaker reported a drastic drop in net loss.
- Ranbaxy sets aside Rs 257.4 crore for impact of USFDA banRanbaxy Laboratories has set aside Rs 257.4 crore towards the financial impact of a US ban on import of products made at its plant at Toans...
- Ranbaxy suspects staff behind Toansa plant woesRanbaxy Laboratories, the troubled drugmaker, has hinted at the possibility of sabotage by disgruntled employees at its manufacturing facil...
- Ranbaxy's Toansa plant under Indian drug regulator's watch tooIndia’s drug regulator has ordered Ranbaxy to furnish a comprehensive explanation for the violation of manufacturing practices at its Toans...
- EU, UK evaluating FDA findings on Ranbaxy's Toansa facilityDays after US FDA banned import of Ranbaxy products to America from its Toansa plant, health regulators of EU & UK have said they are evalu...
- Flies in Ranbaxy's Toansa plant's sample storage room,says FDAOther lapses included usage of un-calibrated and unqualified instruments in laboratory, said the report, which was released two days ago.
- Ranbaxy a lost case? Investors better off selling the stockToansa is the key active pharmaceutical ingredients facility and an alert is likely to put further pressure on business at least in the sho...
- USFDA bars products from Ranbaxy's Toansa plant citing data integrity violationsThe USFDA said Ranbaxy is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa in Punjab.
- Is Ranbaxy a contra buy? Stock slips 19% on USFDA import alertRanbaxy Laboratories Ltd plunged as much as 19.90 per cent in trade on Friday, after the US Food and Drug Administration import alert.
- USFDA ban on Toansa plant disappointing: RanbaxyTerming the USFDA ban on its Toansa plant 'disappointing', Ranbaxy Laboaratories today said it will take 'appropriate management action' fo...
- Ranbaxy plunges 20% as USFDA halts drug imports from Toansa plantRanbaxy Labs plunged as much as 19.69% , after the USFDA ban effectively stops the company from shipping drugs from its Toansa plant.
- Ranbaxy falls 8% on reports USFDA inspecting Punjab unitThe Toansa plant is crucial for the company as about 70 per cent of APIs used in its formulations are said to be manufactured there.
Load More
